Form 4: C4 Therapeutics Director Laura Bessen Acquires Stock Options
SEC Form 4 Filing
Director Laura Bessen acquired stock options in C4 Therapeutics, Inc. on June 20, 2024.
Summary
- On June 20, 2024, Laura Bessen, a director of C4 Therapeutics, Inc., acquired 32,500 stock options at an exercise price of $4.05.
- These options vest fully on the earlier of June 20, 2025, or the next annual meeting of the Issuer's stockholders, contingent upon continued service on the Board.
- Following the transaction, Bessen directly owns 32,500 derivative securities.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing detailing the acquisition of stock options by a company director. It doesn't inherently convey positive or negative sentiment.
Future Outlook
The stock options vest upon continued service as a member of the Board, indicating an incentive for continued involvement with C4 Therapeutics.
Industry Context
Form 4 filings are standard disclosures required by the SEC when insiders such as directors and officers trade in their company's stock, providing transparency to the market.
Stakeholder Impact
- The acquisition of stock options by a director can signal confidence in the company's future performance to shareholders.
Key Dates
| Date | Description |
|---|---|
| 06/20/2024 | Date of transaction: Laura Bessen acquired stock options. |
| 06/20/2025 | Earliest vesting date for the stock options. |
| 06/19/2034 | Expiration date of the stock options. |
| 06/21/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.